Mayo Clinic trial to evaluate folate receptor alpha-targeted breast/ovarian cancer vaccine

Links shared publicly online about this topic.

121
total visits

Mayo Clinic trial to evaluate folate receptor alpha-targeted breast/ovarian cancer vaccine

VaxOnco, a leading oncology biopharmaceutical company, today announced that following FDA IND approval, it will sponsor a Phase I folate receptor alpha-targeted therapeutic vaccine clinical trial in disease-free patients, previously diagnosed with either breast or ovarian cancer at Mayo Clinic.

View full resource at news-medical.net

Tags: Vaccination, Cancer, Vitamin, Healthcare, Vaccine, Mayo Clinic, Oncology, News